Managers / Q2 2022 · view latest →
Lynx1 Capital Management LP
CIK 0001910456 · D81 CALLE C, SUITE 301 PMB 1202, DORADO, 00646 · 703-963-7214
Summary
Lynx1 Capital Management LP reported $117M in U.S.-listed holdings across 12 positions for Q2 2022.
The portfolio is heavily concentrated: BLU alone accounts for 22.3% of reported value.
Compared with Q1 2022, the fund opened 1 new position and exited 3.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 69.2% · $81M
- Other · 30.8% · $36M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| VTLUSDIMMUNIC INC | NEW | +1.10M | 1.10M | +$4M | $4M |
| PASSAGE BIO INC | ADDED | +315.9K | 421.4K | +$668,000 | $995,000 |
| AEROVATE THERAPEUTICS INC | ADDED | +124.6K | 191.6K | +$2M | $3M |
| PIRSEURPIERIS PHARMACEUTICALS INC | ADDED | +2.09M | 3.22M | +$3M | $6M |
| KNTEUSDKINNATE BIOPHARMA INC | ADDED | +982.2K | 1.67M | +$13M | $21M |
| TVTXTRAVERE THERAPEUTICS INC | SOLD OUT | −411.7K | 0 | −$11M | $0 |
| IMGNEURIMMUNOGEN INC | SOLD OUT | −1.54M | 0 | −$7M | $0 |
| ELEVATION ONCOLOGY INC | SOLD OUT | −10.0K | 0 | −$25,000 | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | BLUBELLUS HEALTH INC NEWhistory → | COM NEW | 22.29% | $26M | 2.83M |
| 2 | MERUS N V | COM | 19.31% | $23M | 1.00M |
| 3 | KNTEUSDKINNATE BIOPHARMA INChistory → | COM | 17.99% | $21M | 1.67M |
| 4 | NVLSEURALPINE IMMUNE SCIENCES INChistory → | COM | 13.97% | $16M | 1.93M |
| 5 | CYMABAY THERAPEUTICS INC | COM | 6.51% | $8M | 2.59M |
| 6 | PARDES BIOSCIENCES INC | COM | 5.70% | $7M | 2.18M |
| 7 | PIRSEURPIERIS PHARMACEUTICALS INChistory → | COM | 5.14% | $6M | 3.22M |
| 8 | VTLUSDIMMUNIC INChistory → | COM | 3.26% | $4M | 1.10M |
| 9 | AEROVATE THERAPEUTICS INC | COM | 2.55% | $3M | 191.6K |
| 10 | THESEUS PHARMACEUTICALS INC | COM | 2.38% | $3M | 504.9K |
| 11 | PASSAGE BIO INC | COM | 0.85% | $995,000 | 421.4K |
| 12 | OTICEUROTONOMY INC | COM | 0.05% | $62,000 | 30.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $633M | 23 | May 4, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $494M | 22 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $491M | 14 | Nov 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $346M | 15 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $279M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $267M | 18 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $282M | 18 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024REVEALED | $277M | 18 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024REVEALED | $388M | 16 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $254M | 15 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $151M | 18 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $153M | 18 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $120M | 13 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $116M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $111M | 12 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $117M | 12 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $108M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $115M | 10 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Lynx1 Capital Advisors LLC
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.